1-7 of 7
Sanjeev Luther
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

iPSC-derived mesenchymal stromal cells (iMSC) provide superior support for hematopoietic reconstitution compared to BM-MSCs

Free
Olayinka Okeleji, Sandeep Singh, Andrea Bedoy, Lauren Ostermann, Kyle M. Garland, Po Yee Mak, Christopher Pacheco, Edward Ayoub, Ivo Veletic, Matthew Angel, Sanjeev Luther, Christopher Rohde, Michael Andreeff
Journal: Blood
Blood (2025) 146 (Supplement 1): 4957.
https://doi.org/10.1182/blood-2025-4957
Published: 2025
Journal Articles

Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct  Pro-inflammatory tmes

Free
Muharrem Muftuoglu, Sandeep Singh, Andrea Bedoy, Li Li, Mahesh Basyal, Nath Dipmoy, Lauren Ostermann, Ivo Veletic, Christopher Pacheco, Po Yee Mak, Edward Ayoub, Taeyun Kim, Kyle Garland, Robert Pierce, Mathew Angel, Sanjeev Luther, Christopher Rohde, Michael Andreeff
Journal: Blood
Blood (2025) 146 (Supplement 1): 263.
https://doi.org/10.1182/blood-2025-263
Published: 2025
Journal Articles

Engineered IL7/IL15 secreting iPSC-derived mesenchymal stromal cells reprogram the immunosuppressive tumor microenvironment and potentiate antitumor immunity

Free
Sandeep Singh, Andrea Bedoy, Muharrem Muftuoglu, Li Li, Olayinka Okeleji, Nath Dipmoy, Lauren Ostermann, Ivo Veletic, Christopher Pacheco, Mahesh Basyal, Taeyun Kim, Kyle M. Garland, Mathew Angel, Sanjeev Luther, Christopher Rohde, Michael Andreeff, Vivek Anand
Journal: Blood
Blood (2025) 146 (Supplement 1): 4137.
https://doi.org/10.1182/blood-2025-4137
Published: 2025
Journal Articles

Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma

Free
Raphael Steiner, Liana Nikolaenko, Swetha Kambhampati, Niloufer Khan, Ranjit Nair, Jeremy S. Abramson, Steven Horwitz, Matthew Matasar, Colette Owens, Ildefonso Ismael Rodriguez Rivera, David J. Straus, Timothy S Pardee, Sanjeev Luther, Win Su Thet, Shreya Vemuri, Ariela Noy
Journal: Blood
Blood (2024) 144 (Supplement 1): 1729.
https://doi.org/10.1182/blood-2024-202459
Published: 2024
Journal Articles

Complete Remission with Devimistat (CPI-613) in Refractory Burkitt Lymphoma

Free
Liana Nikolaenko, Timothy Pardee, Raphel Steiner, Jeremy S. Abramson, Steven M. Horwitz, Matthew J. Matasar, Colette Owens, Ildefonso Rodriguez-Rivera, David J. Straus, Sanjeev Luther, Ariela Noy
Journal: Blood
Blood (2021) 138 (Supplement 1): 4555.
https://doi.org/10.1182/blood-2021-153662
Published: 2021
Journal Articles

Multicentre, Open Label, Randomized Phase III Study of Cpi-613 ® (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥ 60 years) with Relapsed / Refractory Acute Myeloid Leukemia (AML) - Armada 2000 (AML003) Trial

Free
Timothy S. Pardee, MD PhD, Sanjeev Luther, MBA, Marc E. Buyse, ScD, Bayard L Powell, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2658.
https://doi.org/10.1182/blood-2019-129377
Published: 2019
Journal Articles

A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6

Free
Ariela Noy, MD, Timothy S. Pardee, MD PhD, Liana Nikolaenko, MD, Raphael Eric Steiner, MD, Jeremy S. Abramson, MD MMSc, Kieron Dunleavy, MD, Sanjeev Luther, MBA
Journal: Blood
Blood (2019) 134 (Supplement_1): 4087.
https://doi.org/10.1182/blood-2019-131563
Published: 2019